<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548002</url>
  </required_header>
  <id_info>
    <org_study_id>210275</org_study_id>
    <nct_id>NCT00548002</nct_id>
  </id_info>
  <brief_title>Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia</brief_title>
  <acronym>FINLEVO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard
      treatment, could reduce the high mortality and complication rates in Staphylococcus aureus
      bacteremia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Case fatality rate</measure>
    <time_frame>At 28 days and at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of complications (e.g. deep infections) observed after the first week antibiotic treatment, decrease in serum C-reactive protein concentration, length of antibiotic treatment, need for surgical intervention, and time to defervescence.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">430</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <condition>Bacteremia</condition>
  <condition>Endocarditis</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1 and 2</arm_group_label>
    <description>Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trovafloxacin and levofloxacin</intervention_name>
    <description>Trovafloxacin: &lt;60 kg 200 mg iv/orally once daily and &gt;60 kg 300 mg iv/orally once daily Levofloxacin: &lt; 60 kg 500 mg iv/orally once daily and &gt;60 kg 500 mg iv/orally bid</description>
    <arm_group_label>1 and 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with at least 1 blood culture positive for Staphylococcus aureus were
        included within 1 to 7 days of blood culture sampling.
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients with at least 1 blood culture positive for Staphylococcus aureus were
        included within 1 to 7 days of blood culture sampling.

        Exclusion Criteria:

          -  age younger than 18 years

          -  imprisonment

          -  proven or suspected pregnancy

          -  breastfeeding, epilepsy

          -  another bacteremia during the previous 28 days

          -  polymicrobial bacteremia (_&gt;3 microbes)

          -  history of allergy to any quinolone antibiotic

          -  previous tendinitis during fluoroquinolone therapy

          -  prior fluoroquinolone use for more than 5 days before randomization

          -  positive culture for Staphylococcus aureus only from a central intravenous catheter

          -  neutropenia (&lt;0.5 x 109/L) or failure to supply an informed consent

          -  patients with bacteremia due to methicillin-resistant S. aureus and a S. aureus strain
             resistant to any fluoroquinolone

          -  patients with meningitis at the time of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eeva Ruotsalainen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>HUS</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <results_reference>
    <citation>Ruotsalainen E, Järvinen A, Koivula I, Kauma H, Rintala E, Lumio J, Kotilainen P, Vaara M, Nikoskelainen J, Valtonen V; Finlevo Study Group. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med. 2006 Feb;259(2):179-90.</citation>
    <PMID>16420547</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruotsalainen E, Sammalkorpi K, Laine J, Huotari K, Sarna S, Valtonen V, Järvinen A. Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients. BMC Infect Dis. 2006 Sep 11;6:137.</citation>
    <PMID>16965625</PMID>
  </results_reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2007</study_first_posted>
  <last_update_submitted>October 22, 2007</last_update_submitted>
  <last_update_submitted_qc>October 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2007</last_update_posted>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>bacteremia</keyword>
  <keyword>endocarditis</keyword>
  <keyword>sepsis</keyword>
  <keyword>fluoroquinolone</keyword>
  <keyword>rifampin</keyword>
  <keyword>levofloxacin</keyword>
  <keyword>trovafloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Trovafloxacin</mesh_term>
    <mesh_term>Alatrofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

